Loading stock data…
MDCX
$0.33-0.00 (-0.72%)
After Hours$0.33-0.00 (-0.60%)· Last close May 11
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Medicus Pharma Ltd. in the Healthcare sector is trading at $0.33. The stock is currently near its 52-week low of $0.25, remaining 79.1% below its 200-day moving average. Technical signals show neutral RSI of 50 and bullish MACD crossover, explaining why MDCX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.33
Potential Upside
5%
Whystock Fair Value$0.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Medicus Pharma Ltd., a biotech/life sciences company, focuses on developing clinical development programs of therapeutic assets in the United States. It is developing SKNJCT-003, which is in Phase 2 study for the treatment of basal cell carcinoma of ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.34M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
-0.04
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
52467.97%
Volume
Today's trading volume
1.82M
Recent News
EXCLUSIVE: Medicus Sees Strongest Efficacy At Higher Dose In Skin Cancer Study
Medicus Pharma Ltd. on Wednesday reported expanded Phase 2 SKNJCT-003 study data showing a clear dose-response relationship for its Doxorubicin Microneedle Array (D-MNA or SkinJect) for nodular basal cell carcinoma (BCC). The company said the pre-specified analysis builds on previously...
Medicus Pharma reports strong Phase 2 dose response in skin cancer study
Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to discuss new data from a pre-specified expanded dataset analysis of the company’s Phase 2 SKNJCT-003 clinical trial, highlighting a positive dose-response relationship for its Doxorubicin Microneedle Array in the treatment of nodular basal cell carcinoma, the most common form of skin cancer. Bokhari explained that the additional analysis builds on previously reported positive topline results, offering deeper biological, histologic, and safety insights that further strengthen the therapeutic profile of the company’s SkinJect platform. He noted that the findings are consistent with earlier clinical data, including results from the Phase 1 SKNJCT-001 study conducted in 2021 and interim Phase 2 data reported in March 2025, reinforcing the reproducibility and reliability of the treatment approach across multiple studies. The SKNJCT-003 trial was designed as a randomized, double-blind, three-arm Phase 2 study evaluating two different dose levels of microneedle-delivered doxorubicin compared to a device-only control. Conducted across multiple clinical sites, the study enrolled approximately 90 patients diagnosed with nodular basal cell carcinoma, aiming to assess both safety and efficacy in a controlled setting. According to Bokhari, the expanded dataset—verified through centralized pathology review—provides a clearer and more clinically meaningful picture of treatment outcomes. Among the cohorts, the 200-microgram dose at Day 57 emerged as the most promising, demonstrating the strongest and most consistent efficacy signal. These results suggest that the treatment may offer a non-surgical alternative for certain patients, potentially reducing or delaying the need for immediate excision of cancerous lesions. Such an approach could represent a meaningful shift in the standard treatment paradigm for BCC, particularly given the relatively short treatment and evaluation window used in the study. Bokhari added that the data package could support future registration-focused discussions with the U.S. Food and Drug Administration (FDA), including considerations around optimal dosing, patient selection, lesion subtype, and treatment timelines. The company believes these findings position SkinJect as a potentially innovative and practical therapeutic option in the dermatologic oncology space. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #SkinJect #ClinicalTrials #Phase2 #Biotech #Dermatology #SkinCancer #BasalCellCarcinoma #Microneedle #DrugDelivery #Oncology #MedicalInnovation #Healthcare #FDA #Biopharma
Medicus Pharma highlights positive dose-response in updated skin cancer trial results
Medicus Pharma (NASDAQ:MDCX) has reported additional results from a pre-specified expanded dataset analysis of its Phase 2 SKNJCT-003 trial, showing a positive dose-response relationship for its Doxorubicin Microneedle Array (D-MNA) in treating nodular basal cell carcinoma (BCC). The analysis...
Medicus Pharma lobbies Congress on SkinJect regulatory pathway for rare Gorlin syndrome
Medicus Pharma (NASDAQ:MDCX) said on Monday its chief executive and senior leadership team met with US lawmakers on Capitol Hill to seek support for regulatory and policy measures aimed at advancing its SkinJect therapy for patients with Gorlin syndrome, a rare inherited condition linked to...
Medicus Pharma advances Skinject in rare disease – ICYMI
Medicus Pharma (NASDAQ:MDCX) earlier this week outlined progress in advancing its Skinject program, highlighting a newly submitted orphan drug designation application with the US Food and Drug Administration targeting Gorlin syndrome, a rare genetic condition with no approved treatments. In...